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Background: While Canadian ED physicians discharge most syncope patients with no specific further follow-up,
approximately 5% will suffer serious outcomes after ED discharge. The goal of this study is to prospectively identify
risk factors and to derive a clinical decision tool to accurately predict those at risk for serious outcomes after ED
discharge within 30 days.
Methods/Design: We will conduct a prospective cohort study at 6 Canadian EDs to include adults with syncope
and exclude patients with loss of consciousness > 5 minutes, mental status changes from baseline, obvious
witnessed seizure, or head trauma prior to syncope. Emergency physicians will collect standardized clinical variables
including historical features, physical findings, and results of immediately available tests (blood, ECG, and ED cardiac
monitoring) prior to ED discharge/hospital admission. A second emergency physician will evaluate approximately
10% of study patients for interobserver agreement calculation of predictor variables. The primary outcome will be a
composite serious outcome occurring within 30 days of ED discharge and includes three distinct categories: serious
adverse events (death, arrhythmia); identification of serious underlying disease (structural heart disease, aortic
dissection, pulmonary embolism, severe pulmonary hypertension, subarachnoid hemorrhage, significant
hemorrhage, myocardial infarction); or procedures to treat the cause of syncope. The secondary outcome will be
any of the above serious outcomes either suspected or those occurring in the ED. A blinded Adjudication
Committee will confirm all serious outcomes. Univariate analysis will be performed to compare the predictor
variables in patients with and without primary outcome. Variables with p-values <0.2 and kappa values ≥0.60 will
be selected for stepwise logistic regression to identify the risk factors and to develop the clinical decision tool. We
will enroll 5,000 patients (with 125 positive for primary outcome) for robust identification of risk factors and clinical
decision tool development.
Discussion: Once successfully developed, this tool will accurately risk-stratify adult syncope patients; however,
validation and implementation will still be required. This program of research should lead to standardized care of
syncope patients, and improve patient safety.
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Syncope is defined as a sudden transient loss of con-
sciousness followed by spontaneous complete recovery
[1]. In pre-syncope, the patient recovers before losing
consciousness [1]. Each year, it is estimated that approxi-
mately 100,000 syncope visits occur in Canadian EDs ac-
counting for 1% of ED visits [2]. Studies from other
countries report that syncope accounts for 1-3% of all
ED visits [3-5]. Syncope can be caused by a spectrum of
conditions ranging from the benign vasovagal syncope
to life-threatening conditions (e.g. leaking abdominal
aortic aneurysm or ventricular arrhythmia) that can
lead to death and morbidity [6,7]. These life-threatening
conditions can be classified into two distinct categories:
ones that are not evident during ED evaluation (arrhyth-
mias, and the risk of death) that need to be predicted,
and serious underlying conditions that are present
during ED evaluation (e.g. myocardial infarction, serious
structural heart disease, significant hemorrhage, pul-
monary embolism) that need to be detected. Among
ED syncope patients, 7-23% will suffer serious out-
comes within 7–30 days of their visit with approximately
half suffering serious outcomes after ED disposition ei-
ther inside or outside the hospital [7-11]. Our previ-
ous Canadian research suggests, with the present practice
pattern, two-thirds of deaths and 30% of all serious out-
comes that occur after ED discharge, will occur outside
the hospital [2].
The decision to admit patients for evaluation or to
perform a diagnostic workup in the ED are important is-
sues as physicians need to balance the potential for
serious outcomes with the reality of ED overcrowding
and a shortage of in-patient hospital beds. Small pilot
studies report that the yield of diagnostic tests is low
and hospitalization does not improve outcomes [12,13].
Risk-stratification and disposition of syncope patients
is challenging for emergency physicians as valid and
reliable evidence guiding these decisions is lacking
[14,15]. A clinical decision/risk stratification tool for
syncope can help standardize patient evaluation, and
may safely and cost-effectively assist clinicians with
disposition decision.
Clinical decision tools are derived from original re-
search that incorporates variables from history, phys-
ical examination or simple diagnostic tests to either
classify patients at risk or to quantify the risk of de-
veloping serious outcomes. A syncope clinical decision
tool that has undergone all three major stages of develop-
ment (derivation, validation and implementation), does
not currently exist [14,15].
The goal of this study is to prospectively identify risk
factors and to derive a clinical decision tool for risk-
stratification of adult ED syncope patients at risk for ser-
ious outcomes within 30 days of ED discharge.Etiology and prognosis of syncope
Syncope is caused by transient global cerebral hypoper-
fusion either due to decreased cardiac output or exces-
sive vasodilatation or, more commonly, a combination of
both [1]. The causes include: a) reflex (also known as
vasovagal) syncope; b) cardiac syncope; c) orthostatic
hypotension; and d) medications (Additional file 1) [1].
Cardiac syncope is an independent predictor of mortality
and sudden death (24% in cardiac versus 3-4% in non-
cardiac groups), and patients with advanced heart failure
(ejection fraction ≤ 20%) have higher risk of sudden
death at one-year [16-21]. A significant proportion of
patients (13%-59%) will have no cause identified during
their ED visit [2,6,11,16,17,22,23]. Given that high-risk
patients have a mortality rate of 57% within the first
year, a significant proportion of patients are admitted in
the US (51% - 83%) [24-26]. However, a majority (>85%)
of the patients are discharged home in Canada [8]. The
decision to admit is complex and largely based on phys-
ician judgment, experience and risk tolerance. The
evaluation, investigations ordered and admission rates
are highly variable among ED physicians, and vary by in-
stitution and country [3,7-10,18,25-30].
Methodological standards for clinical decision tools
Clinical decision tools are developed to reduce the un-
certainty in medical decision-making [31-34]. Reported
methodological standards for the development and val-
idation of decision tools can be summarized as follows:
[35-37] i) There must be a need for a decision tool be-
cause of the prevalence of the clinical condition and
variability in current practice. Such a need must be a be-
lief among physicians practicing in that area [38]; ii) The
outcome or diagnosis to be predicted must be clearly de-
fined. To reduce the risk of bias, outcome ascertainment
should be made without knowledge of the predictor var-
iables; iii) The clinical findings to be used as predictors
must be clearly defined, standardized, and clinically
sensible and their assessment must be done without the
knowledge of the outcome (Blinded predictor variable
assessment); iv) The reliability or reproducibility of the
predictor variables must be clearly demonstrated; v) To
increase generalizability, the subjects in the study should
be selected without bias and should represent a wide
spectrum of patients with and without the outcome;
vi) The mathematical techniques for deriving the tools
must be clearly explained; vii) Decision tools should be
clinically sensible: have a clear purpose, demonstrate
content validity, must be relevant, concise and easy to
use in the intended clinical context; viii) The accuracy
of the decision tool in classifying patients with (sensi-
tivity) and without (specificity) the targeted outcome
should be demonstrated; ix) Prospective validation on
a new set of patients is an essential step in the evolution
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clinical decision tools are not prospectively validated
to determine their accuracy, reliability, clinical sens-
ibility, or potential impact on practice. This validation
process is very important because many statistically-
derived tools fail to perform well when tested in a
new population. The reason for this poor perform-
ance may be statistical (i.e., overfitting or instability
of the original derived model) or due to differences in
prevalence of disease or differences in the population
or differences in how the decision tool is applied
[39-41]; x) An implementation phase (to demonstrate
the true effect on patient care) is the ultimate test for
a decision tool in terms of effectiveness, uptake and
cost [42].
Previous emergency department syncope studies
There are nine original studies previously published to
predict SAEs in ED syncope patients [7,10,11,24,43-47].
A synopsis of the available instruments and how they
perform against the above-mentioned methodological
standards is given in Table 1. All published studies de-
fine ‘abnormal ECG’ variable differently and none are
based on evidence. The definitions for ‘abnormal ECG’
in published studies are detailed in “Definition of Abnor-
mal Electrocardiogram (ECG) in the Syncope Risk-
Stratification Studies”. All published studies also include
patients with serious outcomes during the ED evaluation
in the derivation cohort. Inclusion of such patients in
tool derivation biases the tool towards the identification
of patients with obvious serious outcomes and leads to
poor performance on external validation. In summary,
there are very few prospective studies that assess for all
short-term serious outcomes; however, all have poor
diagnostic test characteristics and several methodological
flaws that preclude widespread use [7,11,45]. Hence,
there is no well-validated clinical decision tool that exists
to help physicians standardize evaluation of ED syncope
patients and identify those at risk for serious outcomes
within 30 days. We plan to derive a robust tool without
the above listed weaknesses.
Definition of Abnormal Electrocardiogram (ECG) in the
Syncope Risk-Stratification Studies
This section details the variations in the definition of the
‘abnormal ECG’ variable in the different studies.
Martin et al. [17]: Abnormal ECG is defined as
presence of any of the following: atrial fibrillation or
flutter, multifocal atrial tachycardia, junctional or paced
rhythms, frequent or repetitive runs of premature
ventricular contractions or ventricular tachycardia, left
axis deviation, bundle branch block, intraventricular
conduction delay, left or right ventricular hypertrophy,PR interval < 10 seconds, previous myocardial infarction,
II or III degree atrioventricular block. Isolated sinus
bradycardia or sinus tachycardia and non-specific ST-T
wave abnormalities were considered normal.
OESIL (Osservatorio Epidemiologico sulla Sincope
nel Lazio) study: The following ECG abnormalities
were considered abnormal in the OESIL study: 1)
Rhythm abnormalities: Supraventricular tachycardia,
multifocal atrial tachycardia, atrial fibrillation, frequent
or repetitive premature supraventricular or ventricular
complexes, sustained or non-sustained ventricular
tachycardia or paced rhythms; 2) Conduction disorders:
Complete or Mobitz type I or type II atrioventricular
blocks, bundle branch block or intraventricular
conduction delay; 3) Ventricular hypertrophy right or
left; 4) Left axis deviation; 5) Old myocardial infarction;
6) Myocardial ischemia: ST segment and T wave
abnormalities consistent or possible with myocardial
ischemia. Non-specific repolarization abnormalities
were considered normal.
Sarasin et al. [44]: The ECG was considered abnormal
if any one of the following abnormalities were present:
atrial fibrillation, sinus pause ≥ 2 and < 3 seconds, sinus
bradycardia > 35 and ≤ 45 beats per minute, conduction
abnormalities (bundle branch block, second-degree
Mobitz type I atrioventricular block, bifascicular block),
signs of previous myocardial infarction or ventricular
hypertrophy or multiple premature ventricular beats
were present.
Abnormalities worse than the above were considered
diagnostic of the cause of syncope and included: sinus
pause ≥ 3 seconds, sinus bradycardia ≤ 35 beats per
minute, atrial fibrillation with slow ventricular response
defined as RR interval ≥ 3 seconds, Mobitz type II
atrioventricular block, complete atrioventricular block
or symptomatic or sustained ≥ 30 seconds ventricular
tachycardia. Minor abnormalities such as I degree
atrioventricular block, non-specific ST-T wave
abnormalities, sinus tachycardia and premature atrial
contractions were considered normal.
San Francisco Syncope Rule Study: Presence of
non-sinus rhythm and any new changes in comparison
to the previous electrocardiogram was considered
abnormal. If no old electrocardiogram is available then
any changes present are sufficient to classify the
electrocardiogram as abnormal.
STePS (Short-Term Prognosis in Syncope) Study:
ECG was defined as abnormal if any of the following
were present: 1) atrial fibrillation or tachycardia;
2) sinus pause ≥2 seconds; 3) sinus bradycardia with
heart rate ranging between 35 and 45 beats/min;
4) conduction disorders (i.e., bundle branch block,
second-degree Mobitz I atrioventricular block); 5) ECG
signs of previous myocardial infarction or ventricular
Table 1 Emergency department syncope studies
No Year Study Variables Scoring system Endpoints Results1 Strengths Weakness
1 1997 Martin et al. • Abnormal ECG 0 to 4 1-year arrhythmias or
deaths
4.4% score 0 One of the earliest studies Only long-term outcomes
• History of ventricular arrhythmia (1 point for each
item)
• History of CHF 57.6% score 3 or 4 Not validated
• Age >45 years
2 2002 OESIL • Abnormal ECG 0 to 4 1-year mortality 0% score 0 Externally validated for Only long-term outcomes
• History of cardiovascular disease (1 point for each
item)
0.6% score
• Lack of prodrome 14% score 2 up to 6 month outcomes Modest performance for
outcomes up to 6 months
• Age >65 years 29% score 3
53% score 4
3 2003 Sarasin et al. • Age >65 years 0 to 3 Arrhythmias in
unexplained ED
syncope
2% score 0 Studied arrhythmia risk in
unexplained syncope
Only inpatients
• History of CHF (1 point for each
item)
17% score 1 Internal validation on
historical cohort
Abnormal ECG 35% score 2
27% score 3 No external validation
4 2004 San Francisco
Syncope Rule




• History of CHF
• Shortness of breath
• Hematocrit < 30% ≥ 1 item = risk Specificity 56% Most widely validated ECG variable too broad
• Triage systolic BP <90 mmHg Included soft outcomes2
5 2007 Boston
Syncope Rule
• Compilation of 25 plausible variables ≥ 1 item = risk 30-day serious events Sensitivity 97% A thorough list of variables No statistical methods
Specificity 62% Not practical
No external validation
6 2008 STePS • Abnormal ECG ≥ 1 item = risk 10-day and 1-year
events
Not Reported Addresses the role of
admissions to hospital




• Male sex Not validated




2% score <3 First study to incorporate
variables from history
Not generalizable - Syncope
expert always available
• Abnormal ECG and/or heart disease (+3)
• Syncope during effort (+3) 2-year total mortality 13% score 3
• Syncope while supine (+2) 33% score 4
77% score >4 Internal validation 92%
sensitivity
2% score <3






















Table 1 Emergency department syncope studies (Continued)
8 2009 Sun et al. • Age >90 years (+1) Addition of all
items
30-day events among
older (≥ 60 years)
syncope patients
2.5% score −1, 0 First study to risk stratify
older patients
Retrospective
• Male sex (+1)
• History of arrhythmia (+1) 6.3% score 1,2 Can be applied only to older
patients
• Triage systolic BP >160 (+1) Large sample size
• Abnormal ECG (+1)
• Abnormal troponin I (+1) 20% score 3 to 6 Not validated
• Near-syncope (−1)




Sensitivity 87% First study to evaluate the




• Bradycardia ≤50 in ED/pre-hospital
• Positive fecal occult blood on rectal Specificity 66%
• Anemia – Hemoglobin≤ 90 g/L Requires BNP testing that is
not widely available
• Chest pain with syncope
• Q wave on ECG (except in lead III)
• O2 saturation≤ 94% on room air Less than ideal sensitivity
ECG = Electrocardiogram, CHF = Congestive Heart Failure, OESIL = Osservatorio Epidemiologico sulla Sincope nel Lazio, BP = Blood Pressure, STePS = Short-Term Prognosis of Syncope, EGSYS = Evaluation of Guidelines in
Syncope Study, BNP = Brain type or B-type Natriuretic Peptide.
1Results of validation phase when available.
2Soft outcomes = Cortical stroke and hospitalization on return visit with no serious events.
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beats.
EGSYS (Evaluation of Guidelines in Syncope
Study): The abnormalities that classified the ECG as
abnormal in the EGSYS study were: Sinus bradycardia,
atrioventricular block greater than first degree, bundle
branch block, acute or old myocardial infarction,
supraventricular or ventricular tachycardia, left or right
ventricular hypertrophy, ventricular pre-excitation,
long QT and Brugada pattern.
Sun et al. [47]: ECG was considered abnormal if any
of the following were present: non-sinus rhythm, sinus
rhythm with pulse rate < 40 beats/min, Q/ST/T changes
consistent with acute or chronic ischemia, abnormal
conduction intervals (QRS >0.1 milliseconds, QTc >450
milliseconds), left or right ventricular hypertrophy, left
axis deviation, and bundle branch block.
Professional society guidelines
There are also three pertinent clinical guidelines from
professional societies for risk stratification of ED syncope
patients [1,14,48]. The European Society of Cardiology
published guidelines for admission in 2001, 2004 and re-
cently updated them in 2009 (European Society of Cardi-
ology - Guidelines for Admission of Syncope Patients)
[1,49,50]. Studies validating these guidelines either found
no effect or were of poor methodological quality [51,52].
European Society of Cardiology - Guidelines for Admission
of Syncope Patients
The European Society of Cardiology 2001 and 2004 guide-
lines for admission are similar and recommend admission
either for diagnosis or treatment and are as follows:
1. For diagnosis
 Suspected or Known significant heart disease,
 Abnormal ECG – Defined by the presence of any
one of the following abnormalities: Bifascicular
block (left bundle branch block or right bundle
branch block combined with left anterior or left
posterior fascicular block), QRS duration ≥ 0 ·
12 seconds, Mobitz I second degree
atrioventricular block, Asymptomatic sinus
bradycardia (<50 beats/min) or sinoatrial block,
Pre-excited QRS complexes, Prolonged QT
interval, Right bundle branch block pattern with
ST-elevation in leads V1-V3 (Brugada syndrome),
Negative T waves in right precordial leads,
epsilon waves and ventricular late potentials
suggestive of arrhythmogenic right ventricular
dysplasia or Q waves suggesting myocardial
infarction,
 Syncope during exercise or supine,
 Associated severe injury, Family history of sudden death,
 Sudden preceding palpitations before syncope,
 Frequent recurrent episodes, or high suspicion of
cardiac syncope.2. For treatment if the following conditions are the cause
 Cardiac arrhythmias,
 Cardiac ischemia,
 Structural cardiac or cardiopulmonary disease,
 Stroke or focal neurological disorders, or
 For pacemaker insertion.The 2009 guidelines added non-sustained ventricular
tachycardia and severe co-morbidities (severe anemia
and electrolyte disturbances) to the admission criteria.
The American College of Emergency Physicians issued
guidelines for management of ED syncope patients in
2001 and 2007 [48,53]. The 2001 guidelines recommend
admission if any of the following high-risk features is
present: 1) History of congestive heart failure or ven-
tricular arrhythmias, 2) Presence of chest pain or acute
coronary syndrome, 3) Signs of heart failure or valvular
heart disease, or 4) ECG signs of ischemia, arrhythmia,
prolonged QT interval, or bundle branch block. The
guidelines recommend that hospitalization be considered
if any of the following medium-risk features are present:
1) Age >60 years, 2) Abnormal ECG (defined as changes
consistent with acute ischemia, dysrhythmias, or signifi-
cant conduction abnormalities), 3) Family history of sudden
death, or 4) Young patients with unexplained exertional
syncope. One study validated the 2001 guidelines retro-
spectively but outcomes were limited to cardiac syncope
with serious methodological limitations in attributing the
cause of syncope as cardiac [54]. The 2007 guidelines advise
hospitalization if any of the following features are present:
1) Older age with associated comorbidities, 2) Abnormal
ECG (defined as changes consistent with acute ischemia,
dysrhythmias, or significant conduction abnormalities), 3)
Hematocrit <0.3, or 4) History or presence of congestive
heart failure or coronary or structural heart disease. The
2007 guidelines included variables ‘older age with associated
comorbidities’ and ‘abnormal ECG’ that were not clearly
defined and these guidelines have not been validated.
The Canadian Cardiovascular Society published a pos-
ition paper on the standardized approaches to the man-
agement of syncope and identified major and minor risk
factors for short-term events [14]. These risk factors have
not been validated yet. The guideline recommends urgent
cardiac assessment within 2 weeks if any one of the fol-
lowing major risk factors are present: 1) Abnormal elec-
trocardiogram (any bradyarrhythmias, tachyarrhythmia or
conduction disease), 2) History of cardiac disease (ische-
mic, arrhythmic, obstructive, valvular), 3) Hypotension
(systolic blood pressure <90mmHg), or 4) Heart failure
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that an urgent cardiac assessment be considered if any
one of the minor factors is present: 1) Age >60 years,
2) Dyspnea, 3) Anemia (haematocrit <0.30), 4) hyperten-
sion, 5) cerebrovascular disease, 6) family history of sudden
death (age <50 years, or syncope during special situations
(while supine, exercise or with no prodrome).
Objectives
The overall goal of this study is to prospectively identify
risk factors and to derive a clinical decision tool for risk-
stratification of adult ED syncope patients to accurately
predict those at risk for serious outcomes within 30 days
of ED discharge. Specific objectives include:
i. To develop and test standardized clinical
assessments in adult ED syncope patients.
ii. To collect patient characteristics, historical data,
physical examination details, specific ECG
characteristics, duration of cardiac monitoring,
cardiac monitor abnormalities and results of
investigations conducted.
iii. To determine the inter-observer reliability for the
clinical information collected.
iv. To collect data regarding the time of occurrence of
all serious outcomes within 30 days (in the ED, as
inpatient or outside the hospital).
v. To determine the statistical association between
clinical information and occurrence of serious
outcomes within 30 days but after ED discharge.
vi. To use multivariate analysis to identify ECG
abnormalities that is associated with cardiovascular
serious outcomes.
vii. To assess the role of B-type or Brain type
Natriuretic Peptide (BNP) in a subset of patients.
viii. To use multivariate analysis to identify risk factors
associated with serious outcomes within 30 days of
ED discharge.
ix. To develop a highly sensitive and adequately
specific clinical decision tool to guide disposition
decision-making.
x. To use multivariate analysis and develop specific
criteria to identify syncope patients who need
cardiac monitoring in the ED and the optimal
duration of such monitoring to avoid missing
serious outcomes that occur within a few hours.
xi. To assess the potential impact on resource
utilization due to the newly developed clinical
decision tool for 30-day serious outcomes.
xii. To determine emergency physicians’ accuracy in
predicting 30-day serious outcomes.
xiii. To assess for long-term outcomes among ED
syncope patients and develop guidelines for
appropriate follow-up.Methods
Study design and setting
We will conduct a prospective observational cohort study
to enroll ED syncope patients. The study setting will be six
Canadian teaching hospitals with a combined annual ED
volume of approximately 300,000 patient visits (Ottawa
Hospital Civic and General Campuses - Ottawa, ON;
Kingston General Hospital and Hotel Dieu Hospital -
Kingston, ON; Foothills Medical Centre – Calgary, AB;
University of Alberta Hospital – Edmonton, AB).
Study population
We will include adult ED patients with syncope (sudden,
transient loss of consciousness followed by spontaneous,
complete recovery) and exclude those with prolonged
loss of consciousness (>5 minutes), mental status changes
from baseline, witnessed obvious seizure, significant
trauma requiring admission and those with loss of
consciousness due to alcohol intoxication, illicit drug
abuse, or secondary to head trauma.
Patient enrolment
On duty ED physicians or research assistants will screen
consecutive patients presenting with syncope, pre-syncope,
fainting, black out, loss of consciousness, fall, collapse, seiz-
ure, dizziness or light-headedness. ED physicians or re-
search assistants will apply the above-mentioned inclusion
and exclusion criteria on these patients to confirm their
eligibility. We will include patients only once in the study
to avoid double counting. All patients’ assessments will be
made by staff physicians certified in emergency medicine
by the Royal College of Physicians and Surgeons of Canada
and/or the College of Family Physicians of Canada or
emergency medicine residents. Standardized description of
all variables and outcomes will be appended to the data
collection form. Our research team will also orient phys-
ician assessors to the components of the standardized
assessment and definitions of the variables, by regular
presentations and group sessions. Physicians will be asked
to fill the data collection form immediately after their
initial history and physical examination, and will be re-
quested to complete the rest of the form when results of
investigations (blood tests, ECG) that are deemed neces-
sary as per the treating physician are available. Results of
our retrospective phase indicate that a small proportion of
patients do not have blood tests (11%) or an ECG (7%)
performed as part of the ED work-up [2]. While there is
no convincing evidence, guidelines from professional or-
ganizations recommend but do not mandate ECG on all
syncope patients [1,14]. Published studies report that
blood tests are helpful only in a small proportion (2-3%)
of syncope patients [16-18]. As there is lack of strong evi-
dence for performing both ECG and blood tests on all
syncope patients and as the study protocol does not alter
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these tests be performed.
Selection of variables
The variables selected for collection in this study were
chosen based on: 1) A recently concluded comprehen-
sive literature search done as part of developing a pos-
ition statement for the Canadian Cardiovascular Society;
2) Recommendations by a committee of three cardiolo-
gists with decades of syncope research experience, eight
experienced emergency physicians and three methodology
experts; and 3) The results of our previously completed
studies [14,55,56]. Consideration was given to restricting
the variable list as it may affect enrollment efficiency and
time required to complete the physician data collection
form. The variables that will be collected in this study are
provided in Prospective Multicentre ED Syncope Study:
List of Variables Collected and their Definitions.
Prospective Multicentre ED Syncope Study: List of
Variables Collected and their Definitions
1. Variables from History: a) Demographics - age, sex;
b) Details of the event – was it witnessed, any
predisposing factors, position during the episode,
exertion prior to syncope, occurrence and duration of
prodromal symptoms, palpitations prior to syncope,
orthostatic symptoms, any associated symptoms, any
injuries suffered; c) Past Medical History - atrial or
ventricular arrhythmias, congestive heart failure,
coronary or valvular heart disease, cardiomyopathy,
pacemaker or implantable cardioverter-defibrillator
insertion, renal failure, hypertension, diabetes, stroke,
transient ischemic attack, gastrointestinal bleeding,
pulmonary hypertension, pulmonary embolism, deep
venous thrombosis, peripheral arterial disease, seizure,
syncope, malignancy, other cardiac conditions (cardiac
tumors, pericardial disease, congenital coronary
abnormalities, prosthetic valve dysfunction,
myocarditis); d) Personal or Family history of
congenital heart disease, prolonged QT, Brugada
syndrome; e) Family history of sudden deaths;
or f) Medications – exogenous estrogens.
2. Variables from Pre-hospital: a) Arrival by
ambulance; and b) Paramedic findings - first and
the lowest systolic and diastolic blood pressure (BP),
non-sinus rhythm or arrhythmia detected on ambu-
lance rhythm strip/cardiac monitor, symptoms such
as light-headedness/dizziness, syncope/pre-syncope,
or hypotension defined as systolic BP < 90 mmHg
associated with rhythm abnormalities; or any cause
for syncope found by paramedics.
3. Variables from Physical Examination: a) Triage
vital signs - pulse rate, systolic and diastolic BPs,respiratory rate, oxygen saturation; b) Postural systolic
and diastolic BP – lying and after 3 minutes of sitting
or standing if orthostatic symptoms present; c) Lowest
and highest systolic and diastolic BP, and heart rate
recorded; d) Glasgow Coma Scale, score based on
eye opening, verbal and motor response; and
e) Examination findings - presence of murmur,
congestive heart failure, clinical signs of deep venous
thrombosis, tenderness in the abdomen, and presence
of bright red blood per rectum or stool occult blood.
4. Variables from Investigations: a) Laboratory
values - hemoglobin, hematocrit, sodium, potassium,
chloride, glucose, urea, creatinine, creatine kinase,
troponin and Brain Natriuretic Peptide (BNP). If
several values are available we will choose the lowest
values of hemoglobin and hematocrit, most extreme
values of sodium and potassium, and highest values
of urea, creatinine, creatine kinase and troponin.
We will also collect the last available values for
hematocrit and creatinine; b) Radiological
investigations – abnormalities on chest x-ray,
computerized tomography of the head and results of
previous available echocardiogram. c) ECG - rate,
rhythm, axis, QRS duration, PR and corrected QT
interval, and presence of any of the following:
premature atrial or ventricular beats, blocks, ventricular
hypertrophy, old myocardial infarction, new ischemic
changes, or others (delta waves, changes consistent
with Brugada syndrome, arrhythmogenic right
ventricular dysplasia); and c) Cardiac monitor:
Duration of monitoring, arrhythmia detected and
symptoms associated with the arrhythmia.
5. Variables for Disposition and Physician
Judgment: a) Final diagnosis in ED - vasovagal,
orthostatic hypotension, likely cardiac, cause
unknown, or outcome in the ED or pre-hospital
setting; b) Certainty of diagnosis in ED - scaled
from 0 to 100% by the deciles; c) Probability of
SAE occurring within 30 days after leaving the
ED - scaled from 0-5% by each percentile, 10-50%
by the deciles, 75% and 100%; d) Referral: Specialty
to which patient was referred (e.g., cardiology, or
neurology) and when (in ED or as outpatient),
disposition of the patient; e) Outpatient
investigations organized – holter,
echocardiogram or others; and e) Definitive
Treatment – Did the patient/family decline
definitive treatment?
Interobserver reliability
Whenever possible, a second emergency physician blinded
to the findings of the first assessor will collect variables on
the physician data collection form approximately in 10%
of the study patients. This second physician will obtain
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tient that the assessment is being done purely for research
purposes.
Quality assurance
Feedback will be given to physicians regarding any issues
with their data collection or recording. We will not pro-
vide physicians with information regarding the accuracy
or reliability of the individual variables.
Ethical considerations
We have obtained ethics approval from the research ethics
boards of all the study hospitals. All personal identifiers
will be kept strictly confidential and stored separately from
the clinical information collected. We will also explicitly
advise physicians not to alter their patient care for the
study, but to continue with usual care. As there is no
change in patient management, this study poses no threat
to patient safety.
This study is approved by the Research Ethics Boards
of all the study hospitals.
Outcomes
The primary, secondary and long-tem (1-year) outcome
measures are detailed in Prospective Multicentre ED
Syncope Study: List of Serious Adverse Events and their
Definitions. We will assess for outcome occurrence by a
three step approach - first we will use the computerized
hospital patient-tracking system to review the following
records for outcome occurrence at all local adult hos-
pitals: a) ED and inpatient hospital records of return
visits; b) Autopsy reports; c) Outpatient clinical notes;
and d) Results of outpatient investigations. As a second
step we will conduct a 30 day and 1-year telephone
follow-up (with a verbal consent obtained again at the
time of telephone contact) to verify that the patient is alive
and has not sustained any serious outcome. During tele-
phone follow-up, we will ask questions regarding ED or
outpatient clinic visits after the index event, any new diag-
nosis or procedural interventions, and if the cause for
the syncope has been identified. If a patient refuses
telephone follow-up, no further action will be taken
and he/she will be designated as lost to follow-up.
Prospective Multicentre ED Syncope Study: List of Serious
Adverse Events and their Definitions
The primary outcome will be a serious adverse event
(SAE) occurring after ED disposition and within 30 days
of the index event, either inside or outside hospital. SAE
is defined as any one of the following: death, arrhythmia,
myocardial infarction, serious structural heart disease,
aortic dissection, pulmonary embolism, severe pulmon-
ary hypertension, subarachnoid hemorrhage, significant
hemorrhage or procedural interventions to treat a causeof syncope. The definitions of the serious adverse events
are detailed below:
a) Death: due to a cause of syncope or unknown
causes;
b) Arrhythmias: Sustained (> 30 seconds) or
polymorphic ventricular tachycardia; sinus
bradycardia < 40 beats/minute; sick sinus with
alternating sinus bradycardia and tachycardia; sinus
pause > 3 seconds; Mobitz type II atrioventricular
heart block; complete heart block or junctional/
idioventricular rhythm; alternating left and right
bundle branch block; symptomatic (light-
headedness/dizziness, hypotension – systolic BP <
90 mmHg) supraventricular tachycardia with rate >
100/minute; symptomatic atrial flutter or fibrillation
with fast (>100/minute) or slow (RR interval >
3 seconds) ventricular rate; pacemaker or
implantable cardioverter-defibrillator (ICD)
malfunction with cardiac pauses, or an abnormal
electrophysiological study (corrected sinus node
recovery time > 550 milliseconds; His-Ventricular
intervals >100 milliseconds; inducible ventricular
tachycardia for > 30 second; polymorphic ventricular
tachycardia/ventricular fibrillation in patients with
Brugada or ventricular dysplasia or previous cardiac
arrest; symptomatic supraventricular tachycardia,
or Infra-Hisian block);
c) Myocardial infarction: Defined as a clinically
important elevation in troponin or ECG change and
must have been confirmed by the emergency
physician or cardiologist or the most responsible
physician;
d) Identification of serious structural heart disease:
i) aortic stenosis with valve area ≤ 1 cm2; ii)
hypertrophic cardiomyopathy with outflow tract
obstruction; iii) left atrial myxoma or thrombus with
outflow tract obstruction; or iv) pericardial effusion
with ventricular wall motion abnormalities or
pericardial tamponade;
e) Aortic dissection - confirmed by CTchest,
trans-esophageal echocardiogram, MRI or angiography;
f ) Pulmonary embolism – confirmed by VQ scan,
computed tomography scan of the chest or
angiography and the patient should have
received or should have been considered for treatment;
g) Identification of severe pulmonary artery
hypertension – detected by cardiac catheterization
or echocardiography with a mean pulmonary arterial
pressure > 30 mmHg;
h) Subarachnoid hemorrhage - Confirmed by
computed tomography/magnetic resonance imaging
of the brain with or without spinal fluid analysis by
lumbar puncture;
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ciated with detected source of bleeding such as
gastrointestinal bleeding, ruptured abdominal aortic
aneurysm, or ectopic pregnancy that is clinically sig-
nificant to cause syncope in the opinion of the treat-
ing physician or that required transfusion;
j) Procedural interventions - Any interventions
used to treat a cause of syncope. The procedural
interventions include pacemaker and/or
defibrillator insertion, cardioversion for
arrhythmias, surgery for valvular heart disease,
dialysis for electrolyte abnormalities causing
arrhythmia, chest tube/pig tail catheter insertion
for pneumothorax or pleural effusion, or surgery
for abdominal aortic aneurysm or ruptured
spleen.
The secondary outcome will be any of the above-
mentioned SAE occurring in the ED.
We will also collect long-term (1-year) outcomes.
Long-term outcomes include death, arrhythmias, serious
structural heart disease, and cardiac procedural interven-
tions for arrhythmia or structural heart disease. The def-
initions for the long-term outcomes are the same as the
30-day SAEs.
If patient follow-up cannot be achieved by the above-
mentioned two steps, we will review the provincial
health systems database and death records from the pro-
vincial coroner’s office for matching patients. Final de-
termination of serious outcomes occurrence will be
completed by an independent adjudication committee
blinded to the predictor variables comprised of two ED
physicians. In cases of disagreement, a third physician
(ED physicians or internist or cardiologist) will adjudi-
cate the outcome. For serious outcomes that occur or
those detected after ED discharge, we will collect infor-
mation if the outcome was anticipated during ED
evaluation.Data analysis
Data will be entered into a computerized database using
Statistical Analysis System (SAS Institute Inc., Cary, NC,
USA) software. We will ensure accuracy of data entry
with built-in logic checks and also by regular review of
frequency reports. We will calculate the inter-observer
agreement using the kappa coefficient for each variable
in a convenience sample 10% of study patients inde-
pendently assessed by a second emergency physician.
We will consider individual predictor variables with
kappa value ≥0.6 for multivariate analysis [57]. We will
analyze the timing of occurrence of serious outcomes in
ED (to calculate optimal duration patients need to be
monitored in ED) and days of occurrence of outcomesafter ED visit (for insight into follow-up of these
patients).
Univariate analysis
Univariate analysis will be performed to determine the
strength of association between the predictor variables
and serious outcomes. We will choose the appropriate
univariate technique based on the type of data: chi
square test with continuity correction for nominal vari-
ables; unpaired, two tailed t-test for continuous vari-
ables, using pooled or separate variance estimate as
appropriate; and, the Mann–Whitney U test for ordinal
variables. For continuous variables we will assess for the
most discriminative cut point to include in multivariate
analysis.
Multivariate analysis
Variables that are reliable (kappa ≥0.6) and strongly as-
sociated with serious outcomes (p-value <0.2) will be se-
lected for multivariate analysis by logistic regression
using Statistical Analysis System (SAS) software or using
recursive partitioning. We will use multivariate analysis
to identify the risk factors for serious outcomes within
30 days of ED discharge and to derive a clinical decision
tool. When building the model, for missing predictor
variables, we plan to either impute by multiple imputa-
tions or assume as normal if it is in young patients with
obvious vasovagal syncope [58]. We will evaluate inter-
action among predictor variables using Mantel-Haenszel
and logistic model procedures. We will consider appro-
priate combining of variables and use composite vari-
ables for incorporation (e.g. bifascicular block). We will
assess for multicolinearity in the model, a statistical
phenomenon in which two or more predictor variables
are highly correlated. We will also assess for lack of fit
by Hosmer-Lemeshow goodness-of-fit test and for over-
fitting in the model by Akaike information criterion
[59,60]. If difficulties arise in developing a clinical deci-
sion tool with acceptable diagnostic test characteristics,
we will explore the option of building models with sep-
aration of serious events: before and after the 7-day
mark; detection of serious underlying conditions (serious
structural heart disease, aortic dissection, pulmonary
embolism, severe pulmonary hypertension, subarachnoid
hemorrhage or significant hemorrhage) versus prediction
of serious events (arrhythmia or death); separation of
cardiac versus non-cardiac events; and excluding pa-
tients with procedural interventions performed without
evidence of underlying serious condition (e.g. pacemaker
insertion without evidence of bradyarrhythmia). If there
is considerable variation in the ED length of stay among
the study patients, we will also explore the option of the
primary outcome as occurrence of serious outcome
6 hours after ED arrival. The majority of syncope
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(CTAS) 3. As a result, in most Canadian provinces it is
expected that a disposition decision is made within six
hours of arrival. Hence, we will choose a 6 hour cut off
point if needed.
We will aim for a model that is highly sensitive, ad-
equately specific, clinically sensible and acceptable, and
one that will not require any computation or statistical
aids so that it can be easily incorporated into practice.
We will also derive another model (with aim of 100%
sensitivity) to predict patients who will benefit from car-
diac monitoring while in the ED.
Classification performance
As a preliminary validation, we will assess the perform-
ance of the tool by comparing the classification of each
patient against the occurrence of serious outcome. This
will allow 95% confidence interval (CI) estimation for
the sensitivity and specificity of the derived tool. We will
perform an internal validation of the scale across 1,000
replications using the bootstrap method [61]. A more
robust validation will be carried out later.
Resource utilization and physician judgment
We will calculate and compare the actual admission rates
versus hypothetical rates if the new tool were implemented.
We will calculate the proportion of patients with correct
diagnosis made during the ED visit and the proportion of
patients who suffer serious outcome outside the hospital
with no specific follow-up arrangements. From the physician
prediction probabilities and the model for the new scale, we
will calculate and compare the likelihood ratios and area
under the receiver operating characteristic (ROC) curves.
Sample size
5,000 patients will be enrolled at the six study sites.
Since there is no hypothesis being tested, we determined
the sample size based on the number of variables in the
final model and the estimation of precision of the sensi-
tivity of the tool to be derived in the study population.
Previous studies have identified that there must be at
least 10 events per predictor variable in the final model
[62]. For clinical decision tool studies, the specific ap-
proach taken (bound on the error of estimation which is
the width of the 95% CI estimate) is the standard technique
used in sample size calculation for decision tool studies
[63]. Conservatively assuming the prevalence as 2.5%, we
calculated a total sample size of 5,000 patients with 125 pa-
tients suffering serious outcomes within 30-days of ED dis-
charge will be needed to derive the tool.
Methodological issues
We considered the following methodological issues dur-
ing the planning of this study.Exclusion of pre-syncope patients
There is no standardized definition for the symptom
‘pre-syncope’ and published studies are contradictory with
respect to the prognosis of pre-syncope in comparison to
syncope [47,64-66]. One study reports that pre-syncope
has a benign prognosis, [47] another reports that it is a
non-specific symptom with cardiac monitor showing sinus
rhythm when captured [65] while two other studies report
that the prognosis is the same as syncope [64,66]. The
European Society of Cardiology guidelines concluded that
the pathophysiology might be different for pre-syncope
than syncope [1]. Hence, we elected to exclude pre-
syncope patients.
Inclusion of admitted patients
There are no clear guidelines for admission of syncope
patients. Hence, patients are usually admitted based on
subjective physician judgment. It is possible that the same
patient if seen by another emergency physician could be
discharged home from the ED as evident by the wide vari-
ations in admission proportions among physicians, hospi-
tals and countries [7,8,10,25-27]. Inclusion of admitted
patients will allow for more robust risk factor identifica-
tion and derivation of a clinical decision tool with the
highest sensitivity to predict all serious outcomes after ED
disposition. This will avoid misclassification of high-risk
patients as low-risk. We will however classify patients
who suffer serious outcomes during hospital admission as
having occurred in the ED, if their outcome was expected
or suspected during ED evaluation.
30 day versus 7 day outcomes
In Canada and in most western countries, there are no
dedicated ‘syncope clinics’ and follow-up with an in-
ternal medicine specialist or a cardiologist is not gener-
ally possible within 7-days. Our pilot study showed that
a significant proportion (37%) of the serious outcomes
occurred between 7 and 30 days of the index syncope
visit [2]. The patients with serious outcomes occurring
within 7-days of ED visit will benefit the most from in-
patient admission, while those patients who suffer ser-
ious outcomes after 7-days will benefit from expedited
outpatient follow-up. Hence, we will assess for 30-day
outcomes.
Discussion
In Canada, as in many other jurisdictions, there is con-
stant pressure to avoid hospital admission due to ED
overcrowding and bed shortages. Our current practice
fails to identify adult syncope patients at risk for serious
outcomes not evident during ED evaluation, and conse-
quently a small but important number of patients suffer
serious outcomes after ED discharge. This study will
identify risk factors associated with serious outcomes
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We will also derive a clinical decision tool to identify
those syncope patients at risk for short-term SAE and
require emergent testing/treatment and/or admission.
Once the tool is derived, we plan to validate it in a sub-
sequent study. Upon validation, this tool has the poten-
tial to standardize care of syncope patients including
cardiac monitoring and the duration of monitoring in
the ED, disposition and urgency of further investiga-
tions/treatment. The tool has the potential to prevent
morbidity and mortality suffered by syncope patients
outside the hospital and efficiently use in-patient re-
sources. We strongly suspect that once the tool is de-
rived and validated, it will be useful to ED physicians,
cardiologists, internists and family physicians to risk-
stratify adult syncope patients who are at risk for serious
outcomes.Additional file
Additional file 1: Causes of Syncope.Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
All authors listed on the manuscript have made substantial contributions to
the conception and design of the study. GAW made contributions to the
study design and data analyses plan. IGS, MS, HM, BR, EL, AMR, RS collect
data at the sites. VT drafted the article; all other authors revised it critically for
important or intellectual content, and approved the final version.
Acknowledgments
We gratefully acknowledge Dr. Monica Taljaard PhD for statistical help, and
Cathy Clement RN and Angela Marcantonio for their help in manuscript
review, formatting, editing and submission.
This study was funded by the Physicians Services Incorporated Foundation,
the Canadian Institutes of Health Research; and The Ottawa Hospital
Academic Medical Organization Innovation Fund. Dr.
Thiruganasambandamoorthy received salary support from the Heart and
Stroke Foundation of Canada through the Jump Start Resuscitation
Scholarship. Dr. Stiell is a University Health Research Chair, University of
Ottawa. Dr. Rowe is supported by the CIHR as a Tier I Canada Research Chair
in Evidence-based Emergency Medicine through the Government of Canada.
Author details
1Department of Emergency Medicine, University of Ottawa, Ottawa, Canada.
2Ottawa Hospital Research Institute, Clinical Epidemiology Unit, The Ottawa
Hospital, Civic Campus, 1053 Carling Avenue, 6th Floor, Rm F650, Ottawa,
Ontario K1Y 4E9, Canada. 3Department of Epidemiology and Community
Medicine, University of Ottawa, Ottawa, Ontario, Canada. 4Department of
Emergency Medicine, Queen’s University, Kingston, Ontario, Canada.
5Department of Biomedical and Molecular Sciences, Queen’s University,
Kingston, Ontario, Canada. 6Department of Public Health Sciences, Queen’s
University, Kingston, Ontario, Canada. 7Department of Emergency Medicine
and School of Public Health, University of Alberta, Edmonton, Alberta,
Canada. 8Department of Emergency Medicine, University of Calgary, Calgary,
Alberta, Canada. 9Department of Medicine, University of Alberta, Calgary,
Alberta, Canada.
Received: 8 January 2014 Accepted: 19 February 2014
Published: 14 March 2014References
1. Moya A, Sutton R, Ammirati F, Blanc JJ, Brignole M, Dahm JB, Deharo JC,
Gajek J, Gjesdal K, Krahn A, Massin M, Pepi M, Pezawas T, Granell RR, Sarasin
F, Ungar A, Van DJ, Walma EP, Wieling W, Abe H, Benditt DG, Decker WW,
Grubb BP, Kaufmann H, Morillo C, Olshansky B, Parry SW, Sheldon R, Shen
WK, Vahanian A, et al: Guidelines for the diagnosis and management of
syncope (version 2009). Eur Heart J 2009, 30(21):2631–2671. Epub 2009
Aug 27 2009, 30(12).
2. Thiruganasambandamoorthy V, Hess EP, Turko E, Perry JJ, Wells GA, Stiell IG:
Outcomes in Canadian emergency department syncope patients - are
we doing a good job? J Emerg Med 2013, 44(2):321–328.
3. Blanc JJ, L'Her C, Touiza A, Garo B, L'Her E, Mansourati J: Prospective
evaluation and outcome of patients admitted for syncope over a 1 year
period. Eur Heart J 2002, 23(10):815–820.
4. Sarasin FP, Louis-Simonet M, Carballo D, Slama S, Rajeswaran A, Metzger JT,
Lovis C, Unger PF, Junod AF: Prospective evaluation of patients with
syncope: a population-based study. Am J Med 2001, 111(3):177–184.
5. Sun BC, Emond JA, Camargo CA Jr: Characteristics and admission patterns
of patients presenting with syncope to U.S. emergency departments,
1992–2000. Acad Emerg Med 2004, 11(10):1029–1034.
6. Kapoor WN: Evaluation and outcome of patients with syncope. Medicine
1990, 69(3):160–175.
7. Quinn JV, Stiell IG, McDermott DA, Sellers KL, Kohn MA, Wells GA:
Derivation of the San Francisco Syncope Rule to predict patients with
short-term serious outcomes. Ann Emerg Med 2004, 43(2):224–232.
8. Thiruganasambandamoorthy V, Hess EP, Alreesi A, Perry JJ, Wells GA, Stiell IG:
External validation of the San Francisco Syncope Rule in the Canadian
setting. Ann Emerg Med 2010, 55(5):464–472.
9. Quinn J, McDermott D, Stiell I, Kohn M, Wells G: Prospective validation of
the San Francisco Syncope Rule to predict patients with serious
outcomes. Ann Emerg Med 2006, 47(5):448–454.
10. Grossman SA, Fischer C, Lipsitz LA, Mottley L, Sands K, Thompson S,
Zimetbaum P, Shapiro NI: Predicting adverse outcomes in syncope.
J Emerg Med 2007, 33(3):233–239.
11. Reed MJ, Newby DE, Coull AJ, Prescott RJ, Jacques KG, Gray AJ: The ROSE
(risk stratification of syncope in the emergency department) study. J Am
Coll Cardiol 2010, 55(8):713–721.
12. Mendu ML, McAvay G, Lampert R, Stoehr J, Tinetti ME: Yield of diagnostic
tests in evaluating syncopal episodes in older patients. Arch Intern Med
2009, 169(14):1299–1305.
13. Crane SD: Risk stratification of patients with syncope in an accident and
emergency department. Emerg Med J 2002, 19(1):23–27.
14. Sheldon RS, Morillo CA, Krahn AD, O'Neill B, Thiruganasambandamoorthy V,
Parkash R, Talajic M, Tu JV, Seifer C, Johnstone D, Leather R: Standardized
approaches to the investigation of syncope: Canadian Cardiovascular
Society position paper. Can J Cardiol 2011, 27(2):246–253.
15. Serrano LA, Hess EP, Bellolio MF, Murad MH, Montori VM, Erwin PJ, Decker
WW: Accuracy and quality of clinical decision rules for syncope in the
emergency department: a systematic review and meta-analysis.
Ann Emerg Med 2010, 56(4):362–373. e1.
16. Day SC, Cook EF, Funkenstein H, Goldman L: Evaluation and outcome of
emergency room patients with transient loss of consciousness. Am J Med
1982, 73(1):15–23.
17. Martin GJ, Adams SL, Martin HG, Mathews J, Zull D, Scanlon PJ: Prospective
evaluation of syncope. Ann Emerg Med 1984, 13(7):499–504.
18. Kapoor WN, Karpf M, Wieand S, Peterson JR, Levey GS: A prospective
evaluation and follow-up of patients with syncope. N Engl J Med 1983,
309(4):197–204.
19. Kapoor WN, Hanusa BH: Is syncope a risk factor for poor outcomes?
Comparison of patients with and without syncope. Am J Med 1996,
100(6):646–655.
20. Middlekauff HR, Stevenson WG, Stevenson LW, Saxon LA: Syncope in
advanced heart failure: high risk of sudden death regardless of origin of
syncope. J Am Coll Cardiol 1993, 21(1):110–116.
21. Ross J Jr, Braunwald E: Aortic stenosis. Circulation 1968, 38(1 Suppl):61–67.
22. Eagle KA, Black HR: The impact of diagnostic tests in evaluating patients
with syncope. Yale J Biol Med 1983, 56(1):1–8.
23. Ben-Chetrit E, Flugelman M, Eliakim M: Syncope: a retrospective study of
101 hospitalized patients. Isr J Med Sci 1985, 21(12):950–953.
24. Colivicchi F, Ammirati F, Melina D, Guido V, Imperoli G, Santini M, OESIL
(Osservatorio Epidemiologico sulla Sincope nel Lazio) Study Investigators:
Thiruganasambandamoorthy et al. BMC Emergency Medicine 2014, 14:8 Page 13 of 14
http://www.biomedcentral.com/1471-227X/14/8Development and prospective validation of a risk stratification system
for patients with syncope in the emergency department: the OESIL risk
score. Eur Heart J 2003, 24(9):811–819.
25. Birnbaum A, Esses D, Bijur P, Wollowitz A, Gallagher EJ: Failure to
validate the San Francisco Syncope Rule in an independent
emergency department population. Ann Emerg Med 2008,
52(2):151–159.
26. Sun BC, Mangione CM, Merchant G, Weiss T, Shlamovitz GZ, Zargaraff G,
Shiraga S, Hoffman JR, Mower WR: External validation of the San Francisco
Syncope Rule. Ann Emerg Med 2007, 49(4):420–427.
27. Gallagher EJ: Hospitalization for fainting: high stakes, low yield. Ann
Emerg Med 1997, 29(4):540–542.
28. Pires LA, Ganji JR, Jarandila R, Steele R: Diagnostic patterns and temporal
trends in the evaluation of adult patients hospitalized with syncope.
Arch Intern Med 2001, 161(15):1889–1895.
29. Mozes B, Confino-Cohen R, Halkin H: Cost-effectiveness of in-hospital
evaluation of patients with syncope. Isr J Med Sci 1988, 24(6):302–306.
30. Simpson CS, Krahn AD, Klein GJ, Yee R, Skanes AC, Manda V, Norris C:
A cost effective approach to the investigation of syncope: relative
merit of different diagnostic strategies. Can J Cardiol 1999,
15(5):579–584.
31. Stiell IG, Greenberg GH, McKnight RD, Wells GA: Ottawa ankle rules for
radiography of acute injuries. N Z Med J 1995, 108(996):111.
32. Stiell IG, Wells GA, Vandemheen KL, Clement CM, Lesiuk H, De Maio VJ,
Laupacis A, Schull M, McKnight RD, Verbeek R, Brison R, Cass D, Dreyer J,
Eisenhauer MA, Greenberg GH, MacPhail I, Morrison L, Reardon M,
Worthington J: The Canadian C-spine rule for radiography in alert and
stable trauma patients. JAMA 2001, 286(15):1841–1848.
33. Stiell IG, Wells GA, Vandemheen K, Clement C, Lesiuk H, Laupacis A,
McKnight RD, Verbeek R, Brison R, Cass D, Eisenhauer ME, Greenberg G,
Worthington J: The Canadian CT Head Rule for patients with minor head
injury. Lancet 2001, 357(9266):1391–1396.
34. Stiell IG, Greenberg GH, Wells GA, McDowell I, Cwinn AA, Smith NA,
Cacciotti TF, Sivilotti ML: Prospective validation of a decision rule
for the use of radiography in acute knee injuries. JAMA 1996,
275(8):611–615.
35. Wasson JH, Sox HC, Neff RK, Goldman L: Clinical prediction rules.
Applications and methodological standards. N Engl J Med 1985,
313(13):793–799.
36. Stiell IG, Wells GA: Methodologic standards for the development of
clinical decision rules in emergency medicine. Ann Emerg Med 1999,
33(4):437–447.
37. Laupacis A, Sekar N, Stiell IG: Clinical prediction rules: a review and
suggested modifications of methodological standards. JAMA 1997,
277(6):488–494.
38. Graham I, Stiell I, McAuley L: Potential areas for new clinical decision rules:
comparison of North America and Europe [Abstract]. Acad Emerg Med
1999, 15(6):433.
39. Charlson ME, Ales KL, Simon R, MacKenzie CR: Why predictive indexes
perform less well in validation studies. Is it magic or methods? Arch
Intern Med 1987, 147(12):2155–2161.
40. Poses RM, Cebul RD, Collins M, Fager SS: The importance of disease
prevalence in transporting clinical prediction rules. The case of
streptococcal pharyngitis. Ann Intern Med 1986, 105(4):586–591.
41. Wigton RS, Connor JL, Centor RM: Transportability of a decision rule for
the diagnosis of streptococcal pharyngitis. Arch Intern Med 1986,
146(1):81–83.
42. Lee TH: Evaluating decision aids: the next painful step. J Gen Intern Med
1990, 5(6):528–529.
43. Martin TP, Hanusa BH, Kapoor WN: Risk stratification of patients with
syncope. Ann Emerg Med 1997, 29(4):459–466.
44. Sarasin FP, Hanusa BH, Perneger T, Louis-Simonet M, Rajeswaran A, Kapoor
WN: A risk score to predict arrhythmias in patients with unexplained
syncope. Acad Emerg Med 2003, 10(12):1312–1317.
45. Costantino G, Perego F, Dipaola F, Borella M, Galli A, Cantoni G, Dell'Orto S,
Dassi S, Filardo N, Duca PG, Montano N, Furlan R, STePS I: Short- and long-
term prognosis of syncope, risk factors, and role of hospital admission:
results from the STePS (Short-Term Prognosis of Syncope) study. J Am
Coll Cardiol 2008, 51(3):276–283.
46. Del Rosso A, Ungar A, Maggi R, Giada F, Petix NR, De Santo T, Menozzi C,
Brignole M: Clinical predictors of cardiac syncope at initial evaluation inpatients referred urgently to a general hospital: the EGSYS score.
Heart 2008, 94(12):1620–1626.
47. Sun BC, Derose SF, Liang LJ, Gabayan GZ, Hoffman JR, Moore AA,
Mower WR, Mangione CM: Predictors of 30-day serious events
in older patients with syncope. Ann Emerg Med 2009,
54(6):769–778, e1-5.
48. Huff JS, Decker WW, Quinn JV, Perron AD, Napoli AM, Peeters S, Jagoda
AS, American College of Emergency P: Clinical policy: critical issues
in the evaluation and management of adult patients presenting
to the emergency department with syncope. Ann Emerg Med 2007,
49(4):431–444.
49. Brignole M, Alboni P, Benditt D, Bergfeldt L, Blanc JJ, Bloch Thomsen PE,
van Dijk JG, Fitzpatrick A, Hohnloser S, Janousek J, Kapoor W, Kenny RA,
Kulakowski P, Moya A, Raviele A, Sutton R, Theodorakis G, Wieling W, Task
Force on Syncope,European Society of Cardiology: Guidelines on
management (diagnosis and treatment) of syncope. Eur Heart J 2001,
22(15):1256–1306.
50. Brignole M, Alboni P, Benditt DG, Bergfeldt L, Blanc JJ, Bloch Thomsen
PE, van Dijk JG, Fitzpatrick A, Hohnloser S, Janousek J, Kapoor W, Kenny
RA, Kulakowski P, Masotti G, Moya A, Raviele A, Sutton R, Theodorakis
G, Ungar A, Wieling W, Task Force on Syncope,European Society of
Cardiology: Guidelines on management (diagnosis and treatment) of
syncope–update 2004. Europace 2004, 6(6):467–537.
51. Del Greco M, Cozzio S, Scillieri M, Caprari F, Scivales A, Disertori M:
Diagnostic pathway of syncope and analysis of the impact of guidelines
in a district general hospital. The ECSIT study (epidemiology and costs of
syncope in Trento). Italian Heart Journal: Official Journal of the Italian
Federation of Cardiology 2003, 4(2):99–106.
52. McCarthy F, McMahon CG, Geary U, Plunkett PK, Kenny RA, Cunningham CJ,
European Society of C: Management of syncope in the Emergency
Department: a single hospital observational case series based on the
application of European Society of Cardiology Guidelines. Europace 2009,
11(2):216–224.
53. American College of Emergency Physicians: Clinical policy: critical issues in
the evaluation and management of patients presenting with syncope.
Ann Emerg Med 2001, 37(6):771–776.
54. Elesber AA, Decker WW, Smars PA, Hodge DO, Shen WK, American
College of Emergency P: Impact of the application of the American
College of Emergency Physicians recommendations for the
admission of patients with syncope on a retrospectively studied
population presenting to the emergency department. Am Heart J
2005, 149(5):826–831.
55. Thiruganasambandamoorthy V, Alreesi A, Hess E, Perry J, Wells G, Stiell I:
Development of an improved rule to predict short-term serious
outcomes in ED patients with syncope [abstract]. Acad Emerg Med 2009,
16:S5–S273.
56. Thiruganasambandamoorthy V, Hess EP, Turko E, Tran ML, Wells GA,
Stiell IG: Defining abnormal electrocardiography in adult
emergency department syncope patients: the Ottawa
Electrocardiographic Criteria. CJEM Canadian J Emerg Med Care
2012, 14(4):248–258.
57. Kramer MS, Feinstein AR: Clinical biostatistics. LIV. The biostatistics of
concordance. Clin Pharmacol Ther 1981, 29(1):111–123.
58. Donders AR, van der Heijden GJ, Stijnen T, Moons KG: Review: a gentle
introduction to imputation of missing values. J Clin Epidemiol 2006,
59(10):1087–1091.
59. Hosmer DW, Lemeshow S: Applied Logisitic Regression. Hoboken, NJ, USA:
Wiley; 2000.
60. Akaike H: A new look at statistical model identification. IEEE Transcations
on Automatic Control 1974, 19(6):716–723.
61. Efron B, Tibshirani R: Bootstrap methods for standard errors, confidence
intervals, and other measures of statistical accuracy. Statist Sci 1986,
1(1):54–75.
62. Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR: A simulation
study of the number of events per variable in logistic regression
analysis. J Clin Epidemiol 1996, 49(12):1373–1379.
63. Scheaffer RL, Mendenhall W, Ott L: Elementary Survey Sampling. 2nd edition.
Belmont, CA, USA: Duxbury Press; 1979.
64. Grossman SA, Babineau M, Burke L, Kancharla A, Mottley L, Nencioni A,
Shapiro NI: Do outcomes of near syncope parallel syncope? Am J Emerg
Med 2012, 30(1):203–206.
Thiruganasambandamoorthy et al. BMC Emergency Medicine 2014, 14:8 Page 14 of 14
http://www.biomedcentral.com/1471-227X/14/865. Krahn AD, Klein GJ, Yee R, Skanes AC, REVEAL I: Predictive value of
presyncope in patients monitored for assessment of syncope. Am Heart J
2001, 141(5):817–821.
66. Garcia Reverte J, Llamas Lazaro C, Garcia Alberola A, Gomez Zapata M,
Garcia Garcia R, Sanchez Munoz JJ, Martinez Sanchez J, Valdes Chavarri M:
[Prognosis of presyncope in patients with structural heart disease].
Rev Esp Cardiol 2004, 57(7):629–634.
doi:10.1186/1471-227X-14-8
Cite this article as: Thiruganasambandamoorthy et al.: Risk stratification
of adult emergency department syncope patients to predict short-term
serious outcomes after discharge (RiSEDS) study. BMC Emergency
Medicine 2014 14:8.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
